Convergent Genomics
Healthcare Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
425 Eccles Ave Fl 2, South San Francisco...Phone Number
(415) 839-0077Website
www.convergentgenomics.comRevenue
<$5 MillionIndustry
About Convergent Genomics
Convergent Genomics, now part of Veracyte, is dedicated to simplifying and accelerating cancer diagnostics for clinicians and patients through personalized data and actionable insights. They specialize in non-invasive genomic urine testing, particularly for bladder cancer, using advanced liquid biopsy and next-generation sequencing technologies. Their flagship product, UroAmp, allows for early detection and monitoring of cancer risks at a genetic level, significantly changing the timeline for cancer diagnosis and management. The company was founded by a team of cancer biologists, urologic oncologists, and data scientists aiming to improve cancer care outcomes.Explore more
Convergent Genomics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Convergent Genomics
Compare insights from companies similar to Convergent Genomics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Convergent Genomics Tech Stack
A closer look at the technologies used by Convergent Genomics
Top Healthcare Services Companies
Frequently Asked Questions Regarding Convergent Genomics
Sign Up For FreeTo access detailed company insights
Convergent Genomics, now part of Veracyte, is dedicated to simplifying and accelerating cancer diagnostics for clinicians and patients through personalized data and actionable insights. They specialize in non-invasive genomic urine testing, particularly for bladder cancer, using advanced liquid biopsy and next-generation sequencing technologies. Th... Read More
